imrecoxib
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
2
Earliest trial started May 1, 2013 (NCT01985165)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Cyclooxygenase-2INHIBITOR
PTGS2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCN1CC(c2ccc(S(C)(=O)=O)cc2)=C(c2ccc(C)cc2)C1=O- Mol. weight
- 369.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL504535 ↗
Also known as
- imrecoxib
- imrecoxib
- imrecoxib
- imrecoxib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03932006 | Phase 4 | Jun 30, 2016 | Sun Yat-Sen University |
| NCT02426060 | Phase 1 | Jan 1, 2015 | Hengrui Therapeutics, Inc. |
| NCT02456688 | Phase 1 | Jan 1, 2015 | Hengrui Therapeutics, Inc. |
| NCT01985165 | Phase 4 | May 1, 2013 | Hengrui Therapeutics, Inc., Tsinghua University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2013 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Tsinghua University | Academic/Hospital | 1 | 0 | 1 | 2013 |
3 organizations
Page 1 / 1